NeuroMetrix, Inc. (NURO) News

NeuroMetrix, Inc. (NURO): $3.70

0.16 (+4.52%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NURO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 396

in industry

Filter NURO News Items

NURO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest NURO News From Around the Web

Below are the latest news stories about NeuroMetrix Inc that investors may wish to consider to help them evaluate NURO as an investment opportunity.

NeuroMetrix''s Quell Neuromodulator Will Be Tested In Long COVID-19 Syndrome

NeuroMetrix Inc''s (NASDAQ: NURO ) Quell wearable neuromodulation technology will be evaluated for fibromyalgia-like syndrome in individuals with post-acute COVID-19 syndrome (PACS, or "long COVID"). Quell is an advanced, non-invasive neuromodulation technology covered by 22 U.S. utility patents and numerous … Full story available on Benzinga.com

Benzinga | February 24, 2022

NeuroMetrix's Quell Neuromodulator Will Be Tested In Long COVID-19 Syndrome

NeuroMetrix Inc's (NASDAQ: NURO) Quell wearable neuromodulation technology will be evaluated for fibromyalgia-like syndrome in individuals with post-acute COVID-19 syndrome (PACS, or "long COVID"). Quell is an advanced, non-invasive neuromodulation technology covered by 22 U.S. utility patents and numerous international patents. It is the only wearable neuromodulator enabled by a proprietary microchip that provides precise, high-power nerve stimulation in a form factor the size of a credit card.

Yahoo | February 24, 2022

NeuroMetrix Reports that Quell® Wearable Neuromodulator to be Evaluated in Post-Acute COVID-19 Syndrome

WOBURN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell wearable neuromodulation technology will be evaluated for treatment of a fibromyalgia-like syndrome in individuals with post-acute COVID-19 syndrome (PACS, or "long COVID"). The trial will be conducted at the Baylor College of Medicine in collaboration with the National Science Foundation (NSF) funded Center to Stream Healthcare In Place (C2SHIP). The principal investigator is Dr. Bij

Yahoo | February 24, 2022

NeuroMetrix reports Q4 results (NASDAQ:NURO)

NeuroMetrix press release (NURO): Q4 net loss of $1MRevenue of $1.82M (+0.6% Y/Y).

Seeking Alpha | January 27, 2022

NeuroMetrix, Inc.''s (NURO) CEO Dr. Shai Gozani on Q4 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | January 27, 2022

NeuroMetrix Reports Q4 and Full Year 2021 Financial Results

WOBURN, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2021. The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices. Highlights: Q4 revenue of $1.8 million was up slightly from Q4 2020. Full year revenue of $8.3 million increased by 11.9% from the pri

Yahoo | January 27, 2022

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2021 Financial Results Conference Call

WOBURN, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 fourth quarter and full year financial results before the opening of the market on January 27, 2022. The Company will host a conference call at 8:00 a.m., Eastern Time on January 27, 2022 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 844-787-0799 and using th

Yahoo | January 20, 2022

BLNK Stock: 9 Things for Blink Charging Investors to Know About the GM Deal

Blink Charging (BLNK) stock is getting a boost on Tuesday from a deal with General Motors (GM) for its electric vehicle (EV) chargers.

William White on InvestorPlace | January 18, 2022

Market Update: Why Are Stocks Down Tuesday?

It's time for a market update and we're diving into why stocks are down on Tuesday and there's plenty of reasons for today's dip.

William White on InvestorPlace | January 18, 2022

NURO Stock: Why NeuroMetrix Investors Are Feeling No Pain Today

NeuroMetrix (NURO) stock is rocketing higher on Tuesday thanks to the FDA granting it Breakthrough Designation for one of its devices.

William White on InvestorPlace | January 18, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4797 seconds.